---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014798"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:26:00.777067+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q2 2022 net loss $76.8M; pipeline progress, new board member

## Summary
- Net loss $76.8M ($0.71/share) in Q2 2022 vs $193.4M ($2.10) in Q2 2021; prior year included $134.9M ZebiAI acquisition costs.
- Cash $838M as of June 30, 2022, down from $958M at Dec 31, 2021; expected to fund operations into at least 2025.
- Appointed Sekar Kathiresan, CEO of Verve Therapeutics, to board of directors.
- FDA alignment on single-arm trial for RLY-4008 in FGFR2-fusion CCA; interim data showed 62% confirmed partial response (8/13) at 70 mg QD.
- Disclosed new breast cancer programs: selective CDK2 inhibitor, ERα degrader, and RLY-5836; RLY-2608 initial data expected H1 2023.

## SEC filing metadata
- accession: 0000950170-22-014798
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022014798/0000950170-22-014798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022014798/rlay-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014798
- JSON: https://secwatch.observer/filing/0000950170-22-014798.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.